Pre-exposure prophylaxis (PrEP)

Resource
December 30, 2019
We examine acceptability of a long‐acting injectable PrEP among HIV‐uninfected women in Zimbabwe, South Africa and two United States phase 2 trial sites.
News
November 28, 2019

A second case of HIV transmission from someone interrupting their HIV therapy as part of a cure study has been published.

Blog
November 27, 2019
This installment wraps up the ACCESS PrEP blog series and talks about combination prevention, particularly the effects of oral PrEP use on condom use.
Blog
November 27, 2019
The third blog in this ACCESS PrEP blog series addresses health providers’ experiences with oral PrEP services. It explores their knowledge of oral PrEP and concerns about increased risky behaviour. Health providers also expressed concern about the challenges clients faced when accessing oral PrEP and the barriers to uptake, adherence and continuation.
Blog
November 27, 2019
This narrative, the second in the ACCESS PrEP blog series, focuses on PrEP-related side effects. It highlights the determination of some clients to continue using oral PrEP despite the side effects they were experiencing.
Blog
November 27, 2019
This blog is the first in the ACCESS blog series and it gives an overview of the study findings. It explores the motivations that made clients decide to start, continue or stop using oral PrEP, as well as what made certain clients decide not to start taking oral PrEP at all.
Resource
October 22, 2019

BACKGROUND: Heterosexual men in South Africa are a large key population to exposure to HIV, yet preferences for HIV pre-exposure prophylaxis (PrEP) a

Event
September 16, 2019

This webinar, happening Wednesday, September 18th, will explore strategies

Resource
August 29, 2019

The development of topical inserts for the prevention of sexually transmitted infections (STIs), particularly human immunodeficiency virus (HIV), represents a promising alternative to oral and parenteral pre-exposure prophylaxis (PrEP) dosage forms.

Blog
August 27, 2019

“We know that life-changing HIV prevention solutions are available, but it’s critical to think strategically about how an innovation like PrEP is meaningful to our priority users.